Table 4.
Subgroup Analysis of Clinical Outcomes by Prophylactic Treatment Regimen. 1
| Outcome | Cyclosporine + Mycophenolate (n = 40) |
In Vivo T-Cell Depletion + Cyclosporine + Methotrexate (n = 15) |
In Vivo T-Cell Depletion + Cyclosporine + Mycophenolate (n = 16) |
In Vivo T-Cell Depletion + Methotrexate + Mycophenolate (n = 25) |
Methotrexate + Mycophenolate (n = 18) |
Mycophenolate (n = 13) |
|---|---|---|---|---|---|---|
| Time from HSCT to aGVHD diagnosis | ||||||
| Median (Q1, Q3), d | 28.0 (17.5, 35.0) |
57.0 (33.0, 76.0) |
23.0 (15.0, 36.0) |
34.0 (24.0, 44.0) |
25.5 (20.0, 40.0) |
30.0 (27.0, 49.0) |
| Best overall response, n (%) | ||||||
| 6 months | ||||||
| CR | 17 (42.5) | 11 (73.3) | 7 (43.8) | 16 (64.0) | 8 (44.4) | 7 (53.8) |
| VGPR | 0 | 2 (13.3) | 1 (6.3) | 1 (4.0) | 1 (5.6) | 0 |
| PR | 3 (7.5) | 1 (6.7) | 1 (6.3) | 1 (4.0) | 1 (5.6) | 1 (7.7) |
| Mixed disease | 0 | 0 | 0 | 1 (4.0) | 1 (5.6) | 0 |
| PD | 0 | 0 | 1 (6.3) | 0 | 0 | 0 |
| No response | 2 (5.0) | 0 | 0 | 0 | 0 | 0 |
| NA/missing | 18 (45.0) | 1 (6.7) | 6 (37.5) | 6 (24.0) | 7 (38.9) | 5 (38.5) |
| 12 months | ||||||
| CR | 15 (37.5) | 12 (80.0) | 5 (31.3) | 15 (60.0) | 8 (44.4) | 5 (38.5) |
| VGPR | 1 (2.5) | 1 (6.7) | 1 (6.3) | 0 | 0 | 0 |
| PR | 0 | 1 (6.7) | 1 (6.3) | 0 | 0 | 0 |
| Mixed disease | 0 | 0 | 1 (6.3) | 1 (4.0) | 1 (5.6) | 0 |
| PD | 1 (2.5) | 0 | 0 | 0 | 0 | 0 |
| No response | 1 (2.5) | 0 | 0 | 0 | 0 | 0 |
| NA/missing | 22 (55.0) | 1 (6.7) | 8 (50.0) | 9 (36.0) | 9 (50.0) | 8 (61.5) |
| Developed cGVHD, n (%) | ||||||
| Yes | 11 (27.5) | 7 (46.7) | 6 (37.5) | 10 (40.0) | 9 (50.0) | 3 (23.1) |
| NA/missing | 4 (10.0) | 0 | 0 | 0 | 1 (5.6) | 3 (23.1) |
| aGVHD recurrence, n (%) | ||||||
| Yes | 15 (37.5) | 2 (13.3) | 4 (25.0) | 5 (20.0) | 6 (33.3) | 3 (23.1) |
| NA/missing | 0 | 1 (6.7) | 0 | 0 | 0 | 0 |
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CR, complete response; HSCT, hematopoietic stem cell transplantation; NA, not available; PD, progressive disease; PR, partial response; VGPR, very good partial response. 1 Twenty-three patients received “other” prophylactic regimens and are not shown in the table.